Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven NASH~* Circulating fasting leptin \<9 ng/mL (staggered criteria for different BMI levels)~Exclusion Criteria:~* Presence of advanced liver disease (as evidenced by abnormal synthetic function, abnormal prothrombin time or albumin)~* Presence of clinical lipodystrophy~* Presence of other liver disease~* Presence of clinical diabetes (fasting \>126 mg/dL or 2 hour post 75 g-glucose \>200 mg/dL or random glucose \>200 mg/dL with presence of diabetes symptoms or known history of diabetes)~* Any medication for treatment of NASH or obesity~* Presence of HIV~* Inability to give informed consent~* Presence of end-stage renal disease, any type of active cancer, or \>class 2 congestive heart failure ((New York Heart Association Functional Classification System), based on medical history and physical examination~* Presence of any other condition that limits life expectancy to \<2 years~* Active infection (may be transient)~* Any other condition in the opinion of the investigators that may impede successful data collection

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metreleptin treatment group (Type: EXPERIMENTAL): Treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).